ALPHA-CAROTENE FOR INHIBITING THE GROWTH OF CANCER CELLS

Abstract: Pharmaceutical composition for inhibiting the growth of cancer cells, specifically for the treatment of tumors of ectodermal and/or endodermal origin, preferably in a cancer cell growth inhibiting or cancer cell differentiation inducing amounts compri­ sing α-carotene and, if desired, conventional non-toxic carriers, vehicles and addi­ tives, and the use of α-carotene for the manufacture of a medicament for inhibiting the growth of cancer cells, specifically of a medicament for the treatment of tumors of ectodermal and/or endodermal origin, preferably in a cancer cell growth inhibi­ ting or cancer cell differentiation inducing amount.

Description: The present invention relates to the use of a pharmaceutical composition for the manufacture of a medicament for inhibiting the growth of cancer cells and the use of a-carotene for the manufacture of a medicament for inhibiting the growth of cancer cells. These days, cancer is generally treated by surgery, radiotherapy or chemotherapy (treatment with drugs). So far, chemotherapy with drugs acting directly on tumor cells to kill them has been widespread, and thus there have been many proposals as to such drugs. These drugs, however, act not only on tumor cells to kill them but also on normal cells, and thus cannot produce their high therapeutic effects without being accompanied by extremely severe side effects. Under the circumstances, attention has been drawn to drugs for enhancing immunological competence of normal cells to indirectly inhibit growth of tumor cells. Examples of such drugs are Krestin and interferon. The direct effects of such drugs on tumor cells is small but advantageous because of the low side effects. Recently, from the viewpoint of decarcinogenesis of tumor cells (carcinogenesis is not irreversible but reversible, that is, tumor cells can be caused to approach or revert to normal cells), attention has also focused on the use of drugs capable of performing differentiation-inducing action to transform tumor cells into normal cells. These drugs have direct action on tumor cells with less side effects, and thus can be expected to be promising antitumor agents which might have high therapeutic effects. Hitherto agents have been proposed having differentiation-inductive activity, such as prostaglandin E₁ which causes an increase of c-AMP. However, prostaglandin E₁ is so unstable in the human body that it must be drip-infused directly to an affected site for treatment of cancer and must be used in combination with other drugs. Under the circumstances, substances having good differentiation-inductive activity and which can be effectively used as an antitumor drug with stability and low toxicity are desired. Seminars in Oncology, Vol. X, No. 3, 1983, discloses vitamin A as an inhibitor of human cancer. The Lancet, 325-326, Aug. 11, 1984, also discloses anticancerous properties of Vitamin A and furthermore, important medical side effects by prolonged intake of this drug. "The Merck Index", 10. Edition, 1983, pages 258 to 259, mentions α-carotene under the therapeutic category as a Vitamin A precursor. It is, therefore, an object of the present invention to provide superior antitumor agents having differentiation-inductive activity. The inventors have made earnest studies on achieving the abovementioned objects and have found that α-carotene has powerful growth-inhibitory effects on tumor cells and causes a differentiation-inductive effect to transform tumor cells into normal cells, i.e., cause tumor cells to revert back into normal cells. Therefore, α-carotene can be used as a decarcinogenetic agent. Thus, the invention has been accomplished. The medicaments manufactured according to the present invention are useful for inhibiting growth of cancer cells by a method comprising administering an effective amount of α-carotene as an antitumor drug to a mammal. It is contemplated that this method will be useful in the treatment of cancer in various types of warm blooded mammals including lower animals such as rats or mice as well as humans. β-carotene is known to have antitumor activity on the lymphocytic system as disclosed in the paper, Oncology 39 , 33-37 (1982). The antitumor effects of β-carotene are also disclosed by Schwartz et al, "BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS", p. 1130-1135 (1986). No report telling that α-carotene has similar activity has been published. In contrast to β-carotene showing little inhibitory effect on the growth of tumor cells , α-carotene proved to have excellent characteristics as antitumor agent as apparent from the later-described Examples. The inventors have also presented new evidence that α-carotene is superior in de-carcinogenetic activity and thus can be used with good chemotherapeutic effects. Fig. 1 is a microscopic photograph showing the morphological change of GOTO cells in a control cultivation containing no α-carotene; Fig. 2 is a microscopic photograph showing the morphological change of GOTO cells treated with α-carotene after 5 days of cultivation; and Fig. 3 is a graph showing an effect of palm carotene on tumor promoting effect of TPA in DMBA initiated mice. Antitumor drugs manufactured according to the invention contain α-carotene as an effective component. α-Carotene suitable for use in the present invention includes natural and synthetic α-carotenes. Natural α-carotene occurs usually as mixtures with other carotenes, such as β-carotene and γ-carotene. The drugs manufactured according to the invention may contain such a carotene mixture. An especially suitable natural carotene for use in the invention is a preparation (palm carotene) extracted, concentrated and purified from palm oil, which is a red opaque paste-like mixture of carotenes, and in which 25 to 40% by weight of α-carotene, 50 to 70% by weight of β-carotene and less than 10% by weight of other components including carotenoids are mixed. The preparation (palm carotene) has a better solubility in oils and good absorbability in the human body when administered. The producing process of palm carotene is disclosed in UK Patent No. 2160874. Purified and isolated α-carotene from various carotene mixtures may be used in the invention. It is noteworthy that the use of isolated α-carotene as an effective component according to the invention produces as powerful inhibitory effect of the growth of tumor cells and a good differentiation-inductive action as compared with carotene mixture containing a corresponding amount of α-carotene. The purified and isolated α-carotene may be prepared according to conventional methods. Antitumor composition manufactured in accordance with the invention of which an effective component is α-carotene, as above-stated, whether α-carotene only or carotene mixtures containing α-carotene, can be administered alone or in combination with other medicines and via various routes. For instance, α-carotene may be administered by intravenous, subcutaneous or intramuscular injection, topically or orally by a suppository inserted into the rectum. The dose can be set in a wide range (for example, 15 µg to 3 g daily per 1 kg body weight or 1 mg to 10 g daily per adult) in accordance with administration route, the number of administrations, and severity of symptoms. Pharmaceutical compositions manufactured according to the invention can be prepared in various combinations with a suitable amount of a sterile non-toxic carrier and an effective amount of α-carotene by any known method. Preparations are made for oral administration, for example, in the form of soft and hard capsules, tablets, granules, grains, powder, one permitting sustained release of the effective component, liquid or suspension, and for parenteral administration, for example, in the forms of injections, drops and suppositories. Suitable examples of non-toxic carriers for use in the invention are as follows: surface active agents such as sucrose fatty acid ester, fatty acid monoglyceride, propyleneglycol fatty acid ester, sorbitan fatty acid ester or lecithin; binders such as gum arabic, gelatin, sorbit, tragacanth gum or polyvinyl pyrrolidone; vehicles such as sucrose, lactose, starch, crystalline cellulose, manitol, light silicic acid anhydride, magnesium aluminate, magnesium metasilicate aluminate, synthetic aluminum silicate, calcium carbonate, sodium bicarbonate, calcium hydrogenphosphate or calcium carboxymethyl cellulose; lubricants such as magnesium stearate, talc or hardened oil; seasoning or flavoring agents such as sodium chloride, saccharin, orange oil, licorice extract, citric acid, glucose, menthol, eucalyptus oil or malic oil; suspending or wetting agents such as coconut oil, olive oil, sesame oil, peanut oil, soybean oil, not so long chain fatty acid glycerides, safflower oil or soybean phospholipid; carbohydrate derivatives such as celluloses (acetate phthalate (CAP)) or saccharides; acrylic copolymers such as methyl acrylatemethacrylic acid copolymer or methyl methacrylatemethacrylic acid copolymer; polyvinyl derivatives such as dibasic acid monoesters; film forming agents or coating aids. Any conventional methods may be used for obtaining these preparations. Mucous membrances-used preparations and injections may be prepared by conventional techniques. For suspension in or emulsification with distilled water, if applied, can be used soybean oil, peanut oil or not so long chain fatty acid triglyceride as suspending agents, and sucrose fatty acid ester, fatty acid monoglycerides, propylene glycol fatty acid ester, sorbitan fatty acid ester or lecithin. α-Carotene which is an effective component of antitumor drugs according to the invention has a powerful inhibitory effect on the growth of tumor cells and good differentiation-inductive action, and therefore may be used as an appropriate de-carcinogenetic agent. The antitumor pharmaceutical compositions of which the effective component is α-carotene are so low in toxicity that no toxicity appears in doses of 3.5g of α-carotene per kg of body weight in mice as α-carotene. It is stable in the body, which permits large dose administration of it alone without needing concomitant treatment with other drugs, and thus is applied effectively to treatment of not only ectodermal- but also endodermal-origin tumors, such as brain tumors, leukemia, gastric, pancreatic, hepatic or cervic cancers, especially neuroblastoma. Embodiments of the invention, in particular demonstrating the effects of the effective component, will be described in detail. Example 1 Growth-inhibitory effect on a tumor cell Human Neuroblastoma cells (GOTO cells) were spread over a Petri dish (inner diameter 35mm) to make a population of 4 X 10⁴ cells/ml culture medium/dish and incubated for 2 days. On the other hand, a 1% emulsion of palm carotene extracted, concentrated and purified from palm oil (2.15 parts by volume) was mixed with 95% ethanol (7.85 parts by volume) and sterilized. To the tumor cell-cultured dish, 10µℓ of the sterilized palm carotene (the last concentration: 20µM containing α-carotene of 6µM and β-carotene of 14µM.) was added, and incubated for 5 days. Control cultivation was made in the same procedure except the use of a carotene-free emulsion. After completion of cultivation, the number of tumor cells was counted in each dish, and the ratio in number to control was calculated in duplicate to obtain the growth-inhibitory effect of palm carotene on the tumor cell. Besides, the growth-inhibitory effects of α-carotene (2µM added) and β-carotene (2µM added) on the tumor cells were also investigated in the same way as in palm carotene. Differentiation-inductive effect Observation was conducted of α-carotene (2µM added) culture and control culture to note morphological changes in the GOTO cells, and the effect of α-carotene was expressed as the differentiated cell rate (referred to as differentiation index, hereinafter) represented by the following equation: where the term "differentiated cells" means those out of 500 selected-cells (cells found in a dish selected as having a gaugeable projection) having a projection at least twice as long as the major diameter of the cell. The obtained results are given in Tables 1 and 2. Growth-inhibitory effect on tumor cells No. of tumor cells (10⁻⁵ cells/dish) Rate of tumor cell No. to control (%) Control 6.73 - Palm carotene (20µM) 3.01 44.7 The results in Table 1 show that palm carotene containing α-carotene and β-carotene has growth-inhibitory effect on the tumor cells (GOTO cells). The results in Table 2 demonstrates that α-carotene exhibits powerful growth-inhibitory effect on the tumor cell compared with β-carotene having slight similar effect, and it therefore has been proven that α-carotene is involved in the effect of palm carotene. The data in Table 2 also shows, that tumor cells cultivated in the presence of α-carotene became differentiated with the development of projections proper to neuroblasts (morphological differentiation) into normal cells by the action of α-carotene (2µM). Figs. 1 and 2 are microscopic photographs (magnification is 400) of control cells and cells treated with α-carotene (2µM) after 5 days of cultivation, respectively, from which the morphological change of GOTO cells (neuroblasts) caused by α-carotene, that is, the effect of α-carotene to reverse the tumor cell into normal cells, can be clearly seen. Example 2 With human tumor cells shown in Table 3 and 20µM of α-carotene and β-carotene, cultivation was conducted in the same way as in Example 1, and then the numbers of cells in the cultures were counted. The rates in the numbers of those cultures to control culture with carotene-free culture medium were calculated to evaluate the growth-inhibitory effects of the carotenes on tumor cells, and the results are listed in Table 3. Growth-inhibitory effects on different tumor cells Tumor cell α-carotene 20µM (%) β-carotene 20µM (%) Pancreatic cancer (PANC-1) 3.8 40.5 Gastric cancer (HGC-27) 1.3 10.9 Hepatic cancer (HLF) 22.5 77.5 Glioblastoma (A-127) 2.3 42.0 The results in Table 3 show that α-carotene has beneficial effects on various tumor cells to inhibit effectively their growth as compared with β-carotene. Example 3 With human tumor cells shown in Table 4 and 10µM of α-carotene, cultivation was conducted in the same way as in Example 1, and then the numbers of cells in the cultures were counted. The rates in the numbers of those cultures to control culture with carotene-free culture medium were calculated to evaluate the growth-inhibitory effects of the carotene on tumor cells, and the results are listed in Table 4. Tumor cell Rate of Tumor cell number to control (%) Neuroblastoma (GOTO) 1.4 Glioblastoma (A-127) 39.6 Leukemia (HL-60) 33.3 Gastric cancer (HGC-27) 23.5 Pancreatic cancer (PANC-I) 48.1 Hepatic cancer (HLF) 55.0 Cervic cancer (Hela) 77.9 The results in Table 4 also show α-carotene has growth inhibiting effect on various tumor cells regardless of their embryonal origin, i.e. ectoderm and endoderm. Both solid tumors and luekemia cells are sensitive to the treatment with α-carotene. Example 4 30 mice were divided into two groups each consisting of 15 members. The fur on the back of each mice was shaved off over a relatively large area. Dimethyl benzoanthracene (DMBA) acetone solution was applied to the shaved area of each mice (100µg DMBA/mouse). One week after, 12-0-tetradecanol phorbol 13-acetate (TPA) acetone solution was applied to the DMBA-applied area of each mice of one group twice a week (0.5µg TPA/mouse/application) as a control and, on the other hand, TPA acetone solution containing palm carotene (30% of α-carotene, 65% of β-carotene and 5% of other carotenoids) was applied to the DMBA applied area of each mice of another group twice a week (162 n mol palm carotene/mouse/application, and 0.5µg TPA/mouse/application) and the number of tumor-bearing mice in each group was examined. The results are shown in fig. 3. From the results, palm carotene containing α-carotene has an excellent effect on inhibiting the occurrence of cancer. Preparations containing an antitumor agent according to the invention are prepared, for example, by the following procedures: Procedure 1 (Capsule): Palm carotene (100g) is suspended in wheat embryo bud oil (1 kg), and then filled in 1000 gelatin capsules. One to ten capsules are administered daily. Procedure 2 (Injection) Palm carotene (100g), stearic acid monoglyceride (100g), peanut oil (200g), sucroseglycerinstearyl ester (50g), ascorbic acid stearate (20g), and distilled water for injection (9530g) are mixed to form an injectable solution. The preparation is filled in ampoules at a rate of 10ml each ampoule. Procedure 3 (External ointment) Polyethyleneglycol 4000 (150g), polyethyleneglycol 400 (150g) and α-carotene (1g). The preparation is mixed with warming. The external ointment is effective for skin cancer. Procedure 4 (Suppository) Methyl salycylate 0.0350g Pharmasol T-115® (Nissan Chemical Industries, Ltd.) 2.0000g α-carotene 0.0100g

Claims: Use of a pharmaceutical composition comprising α-carotene, and, if desired, conventional non-toxic carriers, vehicles and additives for the manufacture of a medicament for inhibiting the growth of cancer cells. The use of a pharmaceutical composition according to claim 1 for the manufacture of a medicament for use in the treatment of tumors of ectodermal and/or endodermal origin. The use of α-carotene for the manufacture of a medicament for inhibiting the growth of cancer cells. The use according to claim 3, characterized by using α-carotene for the manufacture of a medicament for the treatment of tumors of ectodermal and/or endodermal origin. The use according to one of claims 3 and 4, characterized in that α-carotene is used in a cancer cell growth inhibiting or cancer cell differentiation inducing amount.

Inventors: IWASAKI, RYOZO, NISHINO, HOYOKU, OKABE, AKIO, YOGO, YUKI
Applicants: LION CORPORATION
Application year: 1988
Main classification: A61K31
IPC codes: A61K31